AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28504996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Volume Variation (SVV) before fluid challenge.
Number of subjects: 80
Study 28504996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV) before fluid challenge.
Number of subjects: 80
Study 28505243 — intervention group
Group type: EXPERIMENTAL
Intervention: High dual-task gait cost while counting backward
Number of subjects: 112
Study 28505243 — intervention group
Group type: EXPERIMENTAL
Intervention: High dual-task gait cost while naming animals
Number of subjects: 112
Study 28505243 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow single-task gait velocity (<0.8 m/second)
Number of subjects: 112
Study 28505327 — intervention group
Group type: EXPERIMENTAL
Intervention: SAHA (1 µM)
Number of subjects: 8
Study 28505327 — intervention group
Group type: EXPERIMENTAL
Intervention: SAHA (5-day intraperitoneal administration)
Number of subjects: 8
Study 28505327 — intervention group
Group type: EXPERIMENTAL
Intervention: SAHA (1 µM/24 h)
Number of subjects: 8
Study 28505364 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I measurement using six different immunoassays
Number of subjects: 102
Study 28505364 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative data for IGF-I from the same six assay kits
Number of subjects: 102
Study 28505487 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin refusal self-efficacy
Number of subjects: 397
Study 28505487 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 397
Study 28505487 — intervention group
Group type: COMPARATOR
Intervention: No MAT
Number of subjects: 397
Study 28506243 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 1671
Study 28506243 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for comfort measures over life support
Number of subjects: 1671
Study 28506306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patient education course
Number of subjects: 142
Study 28506306 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment during the study period
Number of subjects: 142
Study 28506306 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mental health
Number of subjects: 142
Study 28506306 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing self-esteem and self-efficacy
Number of subjects: 142
Study 28506306 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem and self-efficacy
Number of subjects: 142
Study 28506390 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g once daily for 13 days with rosuvastatin 40 mg (single dose) co-administered with the 11th dose.
Number of subjects: 111
Study 28506390 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus acetylsalicylic acid 81 mg daily for 14 days with or without OM3-CA.
Number of subjects: 111
Study 28506446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 680
Study 28506446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 680
Study 28506516 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 doses of DTaP vaccine
Number of subjects: 4181
Study 28506516 — intervention group
Group type: EXPERIMENTAL
Intervention: Any DTaP vaccine
Number of subjects: 4181
Study 28506784 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare personnel (HCP) caring for MDRO-colonized patients
Number of subjects: 800
Study 28506784 — intervention group
Group type: COMPARATOR
Intervention: Staff without patient contact
Number of subjects: 800
Study 28506784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 800
Study 28507113 — intervention group
Group type: EXPERIMENTAL
Intervention: Binuclear Cyclopalladated Compound Therapy
Number of subjects: 0
Study 28507113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28507117 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 28507981 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement and preliteracy skill program (1 hour/week for 10 weeks)
Number of subjects: 19
Study 28508253 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBDOX treatment
Number of subjects: 20
Study 28508728 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical circulating clonotypes in plasma
Number of subjects: 51
Study 28508728 — intervention group
Group type: EXPERIMENTAL
Intervention: High International Prognostic Index (IPI) scores of 3-4
Number of subjects: 51
Study 28508728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoma-specific clonotypes
Number of subjects: 51
Study 28508945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation combined with allogenic NK cell immunotherapy
Number of subjects: 60
Study 28508945 — intervention group
Group type: COMPARATOR
Intervention: Simple cryoablation
Number of subjects: 60
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-3-Glucuronide (M3G)
Number of subjects: 20
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-Glucuronide (M6G)
Number of subjects: 20
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 20
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: M3G
Number of subjects: 20
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 20
Study 28510797 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 20
Study 28511653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmal Bharat Abhiyan community mobilisation activities
Number of subjects: 80
Study 28511673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg orally once daily until disease progression or intolerable toxicity
Number of subjects: 104
Study 28511692 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg paricalcitol daily
Number of subjects: 36
Study 28511692 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg paricalcitol daily
Number of subjects: 36
Study 28511692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative VPA thresholds
Number of subjects: 1076
Study 28511695 — intervention group
Group type: COMPARATOR
Intervention: Absolute VPA thresholds
Number of subjects: 1076
Study 28511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative MVPA thresholds
Number of subjects: 1076
Study 28511695 — intervention group
Group type: COMPARATOR
Intervention: Absolute MVPA thresholds
Number of subjects: 1076
Study 28511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative MVPA recommendation
Number of subjects: 1076
Study 28511695 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative VPA recommendation
Number of subjects: 1076
Study 28511695 — intervention group
Group type: COMPARATOR
Intervention: Absolute MVPA, MPA or VPA recommendations
Number of subjects: 1076
Study 28511703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 50
Study 28511709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) after nine cycles of induction chemotherapy.
Number of subjects: 54
Study 28512111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pokémon GO participation
Number of subjects: 167
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Tuesday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Wednesday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Thursday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Friday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Saturday/Sunday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery on Tuesday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery on Wednesday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery on Thursday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery on Friday
Number of subjects: 106473
Study 28512116 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery on Saturday/Sunday
Number of subjects: 106473
Study 28512443 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) at 2 mA applied to the left dorsolateral prefrontal cortex and left temporal cortex.
Number of subjects: 30
Study 28512443 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 30
Study 28513244 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in obese subjects with metabolic syndrome (MO)
Number of subjects: 795
Study 28513244 — intervention group
Group type: COMPARATOR
Intervention: Physical activity in obese subjects without metabolic syndrome (NMO)
Number of subjects: 795
Study 28514251 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal flow modulation
Number of subjects: 274
Study 28514251 — intervention group
Group type: COMPARATOR
Intervention: Unmodulated subjects
Number of subjects: 274
Study 28514281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hyperinsulinemia
Number of subjects: 30
Study 28514281 — intervention group
Group type: COMPARATOR
Intervention: Control (non-HIV-infected individuals)
Number of subjects: 30
Study 28514281 — intervention group
Group type: COMPARATOR
Intervention: Control (HIV-infected individuals)
Number of subjects: 30
Study 28514773 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation using non-frozen peripheral blood stem cells (PBSCs) with conditioning of cyclophosphamide and rituximab.
Number of subjects: 286
Study 28514773 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation using non-frozen PBSCs.
Number of subjects: 286
Study 28514929 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided accelerated hypofractionated proton therapy (AHPT) at 70Gy(RBE) in 28 fractions for low-risk disease
Number of subjects: 215
Study 28514929 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided accelerated hypofractionated proton therapy (AHPT) at 72.5Gy(RBE) in 29 fractions for intermediate-risk disease
Number of subjects: 215
Study 28514929 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided accelerated hypofractionated proton therapy (AHPT)
Number of subjects: 215
Study 28514979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic exchange of central venous catheters
Number of subjects: 0
Study 28514979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic exchange)
Number of subjects: 0
Study 28515062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 28515067 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot consumption
Number of subjects: 0
Study 28515069 — intervention group
Group type: EXPERIMENTAL
Intervention: long-chain PUFA-related genotypes
Number of subjects: 0
Study 28515092 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils with a conventional segmented nucleus
Number of subjects: 3
Study 28515092 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils with a banded nucleus
Number of subjects: 3
Study 28515092 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-suppressing CD62L neutrophils
Number of subjects: 3
Study 28515099 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta NT-proBNP (baseline to 6 months)
Number of subjects: 1665
Study 28515099 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta hs-CRP (baseline to 6 months)
Number of subjects: 1665
Study 28515106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h accelerated diagnostic protocol (2h-ADP) combining hs-cTn, electrocardiogram, and a risk score
Number of subjects: 2525
Study 28515106 — intervention group
Group type: COMPARATOR
Intervention: 2-h algorithm based exclusively on hs-cTn concentrations and their absolute changes
Number of subjects: 2525
Study 28515192 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening model for excessive gambling practices based on gambling behaviours observed on French gambling websites.
Number of subjects: 0
Study 28515192 — intervention group
Group type: EXPERIMENTAL
Intervention: Score to predict whether a gambler is problematic or not, developed from the Canadian Problem Gambling Index and real gambling data.
Number of subjects: 0
Study 28515269 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation (10 mL·d)
Number of subjects: 40
Study 28515791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 42
Study 28515791 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide modified release (MR)
Number of subjects: 42
Study 28515798 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation sites (cg06642177, cg07786668, cg17218495)
Number of subjects: 192
Study 28515798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI)
Number of subjects: 192
Study 28516737 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status intervention
Number of subjects: 0
Study 28516737 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28521737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Adherence Screener (MEDAS)
Number of subjects: 68
Study 28521737 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fish consumption (at least 3 portions)
Number of subjects: 68
Study 28521737 — intervention group
Group type: COMPARATOR
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 68
Study 28521762 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® for 3 months
Number of subjects: 35
Study 28521762 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly®
Number of subjects: 35
Study 28521785 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect With Me (group prenatal care)
Number of subjects: 3000
Study 28521785 — intervention group
Group type: COMPARATOR
Intervention: Individual care (control group)
Number of subjects: 3000
Study 28521822 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-MnIL patients (34.6% prevalence)
Number of subjects: 307
Study 28521822 — intervention group
Group type: EXPERIMENTAL
Intervention: HVMs presence in BG-MnIL patients
Number of subjects: 307
Study 28521822 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA presence in BG-MnIL patients
Number of subjects: 307
Study 28521822 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA presence
Number of subjects: 307
Study 28521822 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA after adjustment for confounders
Number of subjects: 307
Study 28521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-rich plaque (LRP) detected in nonculprit regions
Number of subjects: 1474
Study 28521888 — intervention group
Group type: COMPARATOR
Intervention: No lipid-rich plaque (LRP) detected
Number of subjects: 1474
Study 28521888 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP presence
Number of subjects: 1474
Study 28521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome at index presentation
Number of subjects: 1474
Study 28521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of statin use ≥1 year
Number of subjects: 1474
Study 28521888 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP in patients with NC-MACE
Number of subjects: 1474
Study 28522096 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed sleep-wake phase disorder (DSWPD)
Number of subjects: 40
Study 28522096 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 28522110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, busulfan, and melphalan
Number of subjects: 74
Study 28522110 — intervention group
Group type: COMPARATOR
Intervention: Melphalan (control)
Number of subjects: 74
Study 28522573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, melphalan, and dexamethasone (6 cycles every 4 weeks)
Number of subjects: 50
Study 28522574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib, oral administration, monitored within three hours of administration.
Number of subjects: 0
Study 28522574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib, oral administration, monitored within seven days.
Number of subjects: 0
Study 28522574 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors (control group), not treated with nilotinib.
Number of subjects: 0
Study 28522576 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer cells count
Number of subjects: 51
Study 28522645 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 28522741 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28523161 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium 5,000 U, bid preoperatively upon admission
Number of subjects: 58
Study 28523482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven titration of BIAsp 30
Number of subjects: 155
Study 28523482 — intervention group
Group type: COMPARATOR
Intervention: Physician-driven titration of BIAsp 30
Number of subjects: 155
Study 28523582 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrin-targeting radiopharmaceuticals (200 MBq injection)
Number of subjects: 0
Study 28524735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy nutritional body mass index (BMI)
Number of subjects: 1654
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from physicians
Number of subjects: 355
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from books
Number of subjects: 355
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from the Internet
Number of subjects: 355
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from dietitians
Number of subjects: 355
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from nurses
Number of subjects: 355
Study 28525293 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from other sources
Number of subjects: 355
Study 28525370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic vinorelbine (60 mg on Day 1, 30 mg on Day 2, and 60 mg on Day 4 weekly until progression)
Number of subjects: 12
Study 28525370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic vinorelbine
Number of subjects: 12
Study 28525389 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 265
Study 28525389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 28525886 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (RA)
Number of subjects: 1820
Study 28525886 — intervention group
Group type: COMPARATOR
Intervention: Femoral access (FA)
Number of subjects: 1820
Study 28526003 — intervention group
Group type: EXPERIMENTAL
Intervention: BRFQ (Basic Research Factors Questionnaire)
Number of subjects: 0
Study 28526003 — intervention group
Group type: EXPERIMENTAL
Intervention: BRFQ
Number of subjects: 0
Study 28526012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility preserving procedures
Number of subjects: 100
Study 28526012 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of breast cancer survivors achieving a pregnancy
Number of subjects: 100
Study 28526012 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival outcomes, fetal, obstetrical and paediatric care
Number of subjects: 100
Study 28526024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 28526024 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 28526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-institutional referral
Number of subjects: 34319
Study 28526027 — intervention group
Group type: COMPARATOR
Intervention: Not referred
Number of subjects: 34319
Study 28526031 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention
Number of subjects: 20
Study 28526489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of AAV2-sFLT01
Number of subjects: 19
Study 28526489 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD stages 4 and 5
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eGFR
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus treated with oral medication or insulin
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary status
Number of subjects: 3352
Study 28526542 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR reduction of 10ml/min/1.73m²
Number of subjects: 3352
Study 28526664 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching session plus tailored SMS text messages
Number of subjects: 60
Study 28526664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaching or SMS text messages)
Number of subjects: 60
Study 28526673 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game-based rehabilitation platform (CGR)
Number of subjects: 0
Study 28526673 — intervention group
Group type: COMPARATOR
Intervention: Active control arm
Number of subjects: 0